Sanofi's recovery of exclusive rights to the hypnotic Ambien in April 2002 will not "affect in any way their commitment to Plavix or to the upside opportunity with this product," Lane declares. "We...are both very, very, very, very committed to making this one of the most successful brands in the history of the industry"
You may also be interested in...
FDA's ad division has issued a second letter to Sanofi-Synthelabo citing the company for making superiority claims for its antiplatelet drug Plavix versus aspirin.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011